Cancer vaccine - Merck & Co/Fresh Tracks Therapeutics
Alternative Names: V 930; V932Latest Information Update: 25 Sep 2023
Price :
$50 *
At a glance
- Originator Merck & Co; Vical
- Developer Merck & Co
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer